Abstract

COVID-19 is an infectious disease caused by SARS-CoV-2 that emerged in December 2019 in Wuhan, China. Great efforts have been made to find effective drugs to fight the virus. The aim of the study is to review the possibilities of pharmacological therapy in the management of COVID-19 and the repositioning of drugs, highlighting the main characteristics pointed out, advantages and limitations of the alternatives proposed by the scientific community. The study was descriptive, exploratory, cross-sectional, with a qualitative approach. Therapeutic strategies include antimalarials chloroquine and hydroxychloroquine; antibiotics azithromycin and association with chloroquine; antivirals lopinavir-ritonavir, ribavirin, remdesivir, favipiravir; glucocorticoids; immunoglobulins tocilizumab, sarilumab; convalescent plasma; antiparasitic ivermectin, emetine and anticoagulant heparin. Therapeutic possibilities are underway. However, these possibilities come up against the lack of studies proving their efficiency and effectiveness in large populations, given the recent emergence of the disease caused by SARSCoV-2.

Keywords: SARSCoV-2; COVID-19; Repositioning Drugs; Re

References

1. Gao J., et al. “Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies”. Bioscience Trends1 (2020): 72-73.
2. Maier HJ and Britton P. “Involvement of autophagy in coronavirus replication”. Viruses 4 (2012): 3440-3451.
3. Coronavirus updates (2020).
4. Ronald Dijkman and Lia van der Hoek. “Human Coronaviruses 229E and NL63: Close Yet Still So Far”. Journal of the Formosan Medical Association4 (2009): 270-279.
5. Oosterhof L., et al. “Fatal lower respiratory tract disease with human corona virus NL63 in an adult haematopoietic cell transplant recipient”. Bone Marrow Transplant 45 (2010): 1115-1116.
6. Susanna KP Lau., et al. “Molecular Epidemiology of Human Coronavirus OC43 Reveals Evolution of Different Genotypes over Time and Recent Emergence of a Novel Genotype due to”. Natural Recombination Journal of Virology 21 (2011): 11325-11337.
7. Vabret Astrid., et al. “Detection of the New Human Coronavirus HKU1: A Report of 6 Cases”. NCBI: National Center for Biotechnology Information (2006).
8. Tesini Brenda. “Coronavírus e Síndromes respiratórias agudas (COVID-19, MERS e SARS). MANUAL MSD: Versão Saúde para a Família (2020).
9. “Sírio-Libanês. Previna-se contra o Novo Coronavírus” (2020).
10. “Rede Bibliosus. Novo Coronavírus (Covid-19): informações básicas (2020).
11. Verdecchia P., et al. “ACE-inibitori, sartani e sindrome respiratoria acuta da coronavirus 2 [ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus]”. Giornale Italiano di Cardiologia 5 (2020): 321‐327.
12. Zhang H., et al. “Enzima conversora de angiotensina 2 (ACE2) como um receptor SARS-CoV-2: mecanismos moleculares e potencial alvo terapêutico”. Cuidados Intensivos Med 46 (2020): 586-590.
13. Wang Dawei., et al. “Características clínicas de 138 pacientes hospitalizados com nova pneumonia infectada por coronavírus 2019 em Wuhan, China”. JAMA Network (2020).
14. Cascella M., et al. “Recursos, avaliação e tratamento do Coronavírus (COVID-19)”. In: StatPearls [Internet]. Ilha do Tesouro (FL): StatPearls Publishing (2020).
15. Puja Mehta., et al. “COVID-19: consider cytokine storm syndromes and immunosuppression”. The lancet (2020).
16. Lima Oliveira Amaral. “Claudio Márcio de. Informações sobre o novo coronavírus (COVID-19) (2020).
17. report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) (2020).
18. Araujo Castro de. Fernando Luis S. “Aspectos clínicos e terapêuticos da infecção da COVID-19 (2020).
19. Ministério Da Saúde. “Boletim epidemiológico especial: COE-COVID19 (2020).
20. Savarino A., et al. “Effects of Chloroquine on Viral Infections: An Old Drug Against Today's Diseases?” The Lancet Infectious Diseases (2003).
21. Gautret Philippe., et al. “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial”. International Journal Of Antimicrobial Agents (2020): 1-24.
22. Mehra MR., et al. “Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis”. The Lancet (2020).
23. Katzung BG and Trevor AJ. “Farmacologia básica e clínica”. 13. edition. - Porto Alegre: AMGH (2017).
24. Chu CM., et al. “Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings”. Thorax 59 (2004): 252-256.
25. Liu F., et al. “Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression”. International Journal of Infectious Diseases 95 (2020): 183‐191.
26. Elfiky AA. “Anti-HCV, nucleotide inhibitors, repurposing against COVID-19”. Life Sciences (2020): 248.
27. Khalili JS., et al. “Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID‐19”. Journal of Medical Virology (2020).
29. Chu C., et al. “Role of lopinavir/ ritonavir in the treatment of SARS: initial virological and clinical findings”. Thorax (2004).
30. Eastman RT., et al. “Remdesivir: A Review of Its Discovery and Development Leading to Human Clinical Trials for Treatment of COVID-19 (2020).
31. Zhang L and Zhou R. “Mecanismo de Ligação do Remdesivir à RNA Polimerase Dependente do RNA SARS-CoV-2”. Preprints (2020).
32. Aryal Sagar. “Remdesivir- Mecanismo de Ação, Usos, Síntese e COVID-19”. Microbiology Notes by Sagar Aryal (2018).
33. Wang M., et al. “Remdesivir e a cloroquina inibem efetivamente o novo coronavírus recentemente emergido (2019-nCoV) In vitro”. Cell Research 30 (2020): 269-271.
34. Furuta Youseke., et al. “Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase”. NCBI, National Center for Biotechnology Information (2017).
35. Fabio Reis. “Favipiravir demonstra eficácia no tratamento do Coronavírus. Pfarma (2020).
36. Pilkington Victoria., et al. “A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?” NCBI, National Center for Biotechnology Information (2020).
37. Wu C., et al. “Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China”. JAMA Internal Medicine (2020).
38. Tang C., et al. “Caution against corticosteroid-based COVID-19 treatment”. The Lancet (2020).
39. Scott Lesley J. “Tocilizumab: A Review in Rheumatoid Arthritis”. Drugs 17 (2017): 1865-1879.
40. Chi Zhang., et al. “Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality”. International Journal of Antimicrobial Agents5 (2020).
41. Giambenedetto Simona Di., et al. “COVID‐19 group (Members are listed in the Acknowledgments section) - Off‐label Use of Tocilizumab in Patients with SARS‐CoV‐2”. Infection - Journal of Medical Virology (2020).
42. JT Giles., et al. “Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial”. Arthritis and Rheumatology 72 (2020): 31-40.
43. NEVES Ursula. Sarilumabe pode ser um aliado no combate ao novo coronavírus?” Pebmed. Rio de Janeiro (2020).
44. Wang M., et al. “Remdesivir e a cloroquina inibem efetivamente o novo coronavírus recentemente emergido (2019-nCoV) In vitro”. Cell Research 30 (2020): 269-271.
45. Wang Y., et al. “Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID‐19) implicate special control measures”. Journal of Medical Virology (2020): 25748.
46. REIS Fabio. “Sanofi e Regeneron testam medicamento para casos graves de coronavirus”. PFARMA. Rio de Janeiro (2020).
47. Keith P., et al. “A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19”. Critical Care 24 (2020): 128.
48. Duan K., et al. “Effectiveness of convalescent plasma therapy in severe COVID-19 patients”. Proceedings of the National Academy of Sciences of the United States of America (2020).
49. Dzik and Editor. “COVID-19 Convalescent Plasma: Now Is the Time for Better Science”. Transfusion Medicine Reviews (2020).
50. Golan DE., et al. “Princípios de farmacologia: a base fisiopatológica da farmacoterapia. - 3 ed. Rio de Janeiro:Guanabara Koogan (2014).
51. Gotz V., et al. “Os vírus da gripe A escapam da restrição MxA às custas da importação eficiente de RNP nuclear”. Scientific Reports 6 (2016): 23138.
52. Lundberg L., et al. “Inibidores da importação e exportação nuclear alteram a distribuição de proteínas do capsídeo em células de mamíferos e reduzem a replicação do vírus da encefalite equina venezuelana”. Antiviral Research 3 (2013): 662-672.
53. Tay Meu., et al. “Localização nuclear do vírus da dengue (DENV) 1-4 proteína não estrutural 5; proteção contra todos os 4 sorotipos de DENV pelo inibidor Ivermectina”. Antiviral Research 3 (2013): 301-306.
54. Wagstaff KM., et al. “A ivermectina é um inibidor específico da importação nuclear mediada por importina alfa / beta, capaz de inibir a replicação do vírus HIV-1 e dengue”. A revista Bioquímica3 (2012): 851-856.
55. Caly L. et al. “The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 In vitro”. Antiviral Research (2020): 104787.
56. Bleasel Martin D., et al. “Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses. Bleasel MD1, Peterson GM1)”. Pharmaceuticals 3 (2020). pii: E51.
57. Tang N., et al. “Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy (2020).
58. Hamerschlak Nelson., et al. “Utilização da Heparina e dos Anticoagulantes Orais na Prevenção e Tratamento da Trombose Venosa Profunda e da Embolia Pulmonar”. Arquivos Brasileiros de Cardiologia 3 (2020): 1996.